Jpmorgan Chase & CO Marker Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Shares
3 transactions
Others Institutions Holding MRKR
# of Institutions
5Shares Held
475KCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA354KShares$967,5120.18% of portfolio
-
Ar Asset Management Inc73.7KShares$201,2010.05% of portfolio
-
Personal Capital Advisors Corp25.7KShares$70,1930.0% of portfolio
-
American Portfolios Advisors Holbrook, NY21.2KShares$57,7940.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About Marker Therapeutics, Inc.
- Ticker MRKR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,599,200
- Market Cap $228M
- Description
- Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...